Drug Type Small molecule drug |
Synonyms |
Target |
Action inhibitors |
Mechanism ALDH2 inhibitors(Aldehyde dehydrogenase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC20H17Cl2N2O6P |
InChIKeySPADNYVJQZNTKZ-UHFFFAOYSA-N |
CAS Registry1416975-42-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Opioid-Related Disorders | Phase 2 | - | - | |
Opioid-Related Disorders | Phase 2 | - | - | |
Alcohol Use Disorder | Phase 1 | United States | 08 Oct 2019 | |
Alcoholism | Phase 1 | United States | - | - |
Smoking Cessation | Phase 1 | United States | - | |
Substance-Related Disorders | Phase 1 | United States | - | |
Opium Dependence | Discovery | United States | 01 Mar 2019 |
Phase 2 | 43 | (ANS-6637 - 200mg) | kddrkhudqc(bblxffdbah) = oxipxnaqsc ojjveuuvfl (zlagethvqu, btqlosrjwi - vktekkgard) View more | - | 10 Mar 2022 | ||
(ANS-6637 - 600mg) | kddrkhudqc(bblxffdbah) = vehntmtdzs ojjveuuvfl (zlagethvqu, hzlxjgdpla - pjakjaiudc) View more | ||||||
Phase 1 | 26 | wkiwreyumu(yjpfipbolj) = kyfvqcamwz hgzkoraywx (cnvzdulmhn, fdnvsbuzom - leyawsuqlq) View more | - | 03 Aug 2020 |